3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Postoperative Complications
2
Malnutrition
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder, Neurogenic
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Gastrointestinal Neoplasms
1
Frailty
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
29
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Gemcitabine
13
apatinib
12
Paclitaxel
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
8
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
Immunonutrition Diet
×
Clear all
NCT06840704
2026-04-02
Relief
Hunan Cancer Hospital
Phase 3
Recruiting
121 enrolled